Protagonist Therapeutics
PTGX
274 hedge funds and large institutions have $4.7B invested in Protagonist Therapeutics in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 84 increasing their positions, 109 reducing their positions, and 38 closing their positions.
255% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $3.45M
20% more capital invested
Capital invested by funds: $3.92B → $4.7B (+$772M)
11% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 38
1% more funds holding
Funds holding: 272 → 274 (+2)
0.88% less ownership
Funds ownership: 114.5% → 113.62% (-0.88%)
23% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 109
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$61.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$49.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$37.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$27.9M |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$25.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$87M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$37M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$34.4M |
| 4 |
Holocene Advisors
New York
|
-$29.3M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$22.4M |
PTGX Hedge Fund Activity: Q3 2025 in Review
274 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2025, worth a combined $4.7B — up 20% from $3.92B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PTGX positions and 38 closed out — a net gain of 4 holders — while 84 added to existing stakes and 109 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $61.7M. The largest seller was Deep Track Capital, cutting an estimated $87M.
- 274 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2025, up from 272 in Q2 2025.
- Funds reported $4.7B of Protagonist Therapeutics stock for Q3 2025, up 20% quarter-over-quarter.
- 42 funds opened new Protagonist Therapeutics positions in Q3 2025 and 38 closed out, a net change of +4 holders.
- The largest Protagonist Therapeutics buyer in Q3 2025 was Marshall Wace, an estimated $61.7M added.
- The largest Protagonist Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $87M sold.
Based on aggregated 13F filings for Q3 2025.